Literature DB >> 10553261

Bone marrow transplantation for beta-thalassemia.

C Giardini1, G Lucarelli.   

Abstract

Bone marrow transplantation in thalassemia represents the only form of radical cure of this disease. Patients younger than 17 years are divided into three classes of risk according to the presence or absence of portal fibrosis, hepatomegaly, and history of adequate chelation treatment. Patients older than 16 years are categorized as adult thalassemics. Survival and event-free survival are 93% and 91% for Class 1, 87% and 83% for Class 2, and 79% and 58% for Class 3, respectively. Adult patient survival is 66% and event-free survival is 62%.

Entities:  

Mesh:

Year:  1999        PMID: 10553261     DOI: 10.1016/s0889-8588(05)70109-x

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

Review 1.  Genetic Manipulation Strategies for β-Thalassemia: A Review.

Authors:  Nur Atikah Zakaria; Rosnah Bahar; Wan Zaidah Abdullah; Abdul Aziz Mohamed Yusoff; Shaharum Shamsuddin; Ridhwan Abdul Wahab; Muhammad Farid Johan
Journal:  Front Pediatr       Date:  2022-06-15       Impact factor: 3.569

2.  Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases.

Authors:  Lin Ye; Judy C Chang; Chin Lin; Xiaofang Sun; Jingwei Yu; Yuet Wai Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-29       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.